Gossamer Bio, Inc., a company with six drugs in its pipeline, is planing to go public and has applied to list on the Nasdaq exchange.

from MarketWatch.com - Top Stories https://on.mktw.net/2B9DMFa
via IFTTT
from MarketWatch.com - Top Stories https://on.mktw.net/2B9DMFa
via IFTTT
Kommentare
Kommentar veröffentlichen